In the News

1553 News Items found
MSK neuro-oncologist Ingo Mellinghoff
Experimental Drug for Low-Grade Glioma With IDH Gene Mutation Shows Promise
A new experimental drug could be an effective treatment for some people with low-grade glioma.
See Dr. Deb Schrag standing in a hallway. She led a clinical trial involving rectal cancer at Memorial Sloan Kettering.
Rectal Cancer Treatment Without Radiation: A New Option
Learn about a clinical trial at Memorial Sloan Kettering that gives people with rectal cancer a new option to be treated without radiation. The research shows that a well-known chemotherapy regimen used alone can be just as effective as chemotherapy given with radiation before surgery. The new method may reduce side effects associated with radiation such as loss of fertility and impaired bladder and sexual function.
Dr. James Harding
For Advanced, HER2-Amplified Bile Duct Cancers, Antibody Treatment Trial Shows Promising Results
New research finds an antibody treatment helped shrink tumors in some patients with bile duct cancers — specifically a subset of people whose tumors make a high amount of the HER2 protein, which can cause cells to multiply too quickly.
In the Lab
Dr. Piro Lito
Potential Drug Shows Promise Targeting a Range of KRAS-Driven Cancers in the Lab
MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
Back row from left to right: Zongmin Wang, Miguel Miranda-Román, Stella Paffenholz, Anton Dobrin, Bradley Benjamin, Caroline Gleason, Paige Arnold, and Mollie Chipman. Front row, from left to right: Yasemin Kaygusuz, Maria Sirenko, Buren Li, Tingxu Chen, Nayan Jain, Florisela Herrejon Chavez, and Adele Whaley.
MSK’s 2023 Commencement Celebrates Largest Class in History and Honors Award Winners
MSK's 44th annual Academic Convocation and Commencement celebrated the Gerstner Sloan Kettering Graduate School of Biomedical Sciences class of 2023, honored students graduating from the Sloan Kettering Division of the Weill Cornell Medicine Graduate School of Medical Sciences, and recognized winners of several awards and fellowships.
an composite showing a black and white, historical photo of a woman at the microscope on the left, and a modern version of a similar picture on the right
MSK’s Sloan Kettering Institute Celebrates 75 Years of Discovery
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
An MSK scientist pipettes in the lab
MSK Research Highlights, May 18, 2023
New MSK research shows how high-risk neuroblastoma evolves to be so deadly; finds continued safety and efficacy for sotorasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer; and demonstrates promise in eradicating tumors by delivering a viral-based immunotherapeutic to melanoma and breast cancer in mouse models.
Dr. Grady Nelson interviews a student scientist at the science fair.
MSK Supports STEM Education at Yankee Stadium Science Fair
Three MSK researchers served as guest judges at the event, which celebrated students’ academic achievements.
Dr. Michael Overholtzer
17 Gerstner Sloan Kettering Students Will Graduate This Year
Seventeen scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 17, 2023, as part of Memorial Sloan Kettering’s 44th annual academic convocation.
Dana Pe'er and Scott Lowe
Expansion of Cell-to-Cell Communication Drives the Early Development of Pancreatic Cancer, New Research in Mice Finds
New MSK research combined sophisticated genetically engineered mouse models and advanced computational methods to map the earliest cell states leading to pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer.